Updates are available Correction dated 2023-10-16
Click to view Correction: https://doi.org/10.1038/s42255-023-00923-7
-
Authors
Sa, Moonsun https://orcid.org/0000-0002-5066-7706
Yoo, Eun-Seon https://orcid.org/0000-0002-2401-0620
Koh, Wuhyun https://orcid.org/0000-0002-4398-1094
Park, Mingu Gordon https://orcid.org/0000-0002-9287-5167
Jang, Hyun-Jun https://orcid.org/0000-0002-2261-0067
Yang, Yong Ryoul
Bhalla, Mridula https://orcid.org/0000-0001-6045-3683
Lee, Jae-Hun
Lim, Jiwoon
Won, Woojin https://orcid.org/0000-0001-5262-039X
Kwon, Jea
Kwon, Joon-Ho https://orcid.org/0000-0002-7536-8649
Seong, Yejin https://orcid.org/0000-0001-9727-6342
Kim, Byungeun
An, Heeyoung
Lee, Seung Eun
Park, Ki Duk
Suh, Pann-Ghill
Sohn, Jong-Woo https://orcid.org/0000-0002-2840-4176
Lee, C. Justin https://orcid.org/0000-0002-3555-0980
- License Information
-
More Information
Article History
Received: 23 December 2021
Accepted: 25 July 2023
First Online: 31 August 2023
Change Date: 16 October 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s42255-023-00923-7
Competing interests
: K.D.P. and C.J.L. are inventors on a patent for KDS2010 (US11053190) and related to MAO-B inhibition as an anti-obesity therapy (PCT/KR2015/010104). M.S., K.D.P., and C.J.L. are inventors on a patent for reversible MAO-B inhibitors for treating obesity (KR-10-1746060). These patents have been licensed to Neurobiogen, which develops KDS2010 for the treatment of Alzheimer’s disease and obesity. Additionally, C.J.L. and K.D.P. also received honoraria for speaking engagements from Neurobiogen. The other authors declare no conflict of interest.
